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To me the concept of clinical pharmacy is the
freshest, most invigorating, most challenging and
exciting breeze that has blown across the horizons
of pharmacy in any land for generations.  I hope
that its message will ring loud and clear to
pharmacists all over the world, and that it will be
the source of a new inspiration to pharmacists
everywhere.
Donald E. Francke1
Angaran: We have two main goals in this panel
discussion.  First, to describe the current status
of the health care delivery environment, the
medication use system, and the pharmacy
profession.  And second, to discuss the specific
challenges and opportunities for pharmacy
over the next 5–10 years.  Our hope is that you
identify at least one specific action that you can
apply that will catalyze change in your
professional practice, regardless of your
country of origin.
Our discussion will be in three sections.
The first part will concentrate on the broad
topics of health care and the health care
environment, admittedly from only the
European and United States’ perspectives.  The
second part will deal with pharmacy specifically,
and how pharmacy should respond to these
environmental changes.  And finally, we will
close with specific recommendations from each
panelist.
Bert, you have written about future scenarios
regarding medication use in health care.
Probably every country in the world is faced
with a demand for health care that exceeds the
resources available to support that health care.
In the U.S., spending on prescription pharma-
ceuticals constitutes 7–11% of total health care
expenditures—and that percentage is rising.
Further, the cost of pharmaceuticals is rising at
a faster rate than any other segment of health
care.  Recognizing that differences exist among
countries, can you provide a perspective on the
current status of health care systems in Europe
and comment on important trends that you
envision over the next 5 years?
Leufkens: Just as is true in the U.S., the health
care environment is changing very rapidly in
most of Europe.  Some major trends that are
affecting patients and health care providers
include technologic and information science
advances, a changing European economy, a
shift in disease burden, and of course,
European harmonization.  To give an example
of how changing disease burden is affecting the
health care system, we are doing a project on
congestive heart failure and have observed a
tremendous increase in its prevalence—partly
because we have improved our treatment of
acute myocardial infarction.  Thus, as we
reduced mortality from an acute medical
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problem, we increased the prevalence of a
chronic disease that requires long-term
management.  This kind of shift will have a
great impact on health care resource utilization.
Of course, those who pay for health care—
largely the government in most European
countries—are placing increased emphasis on
controlling costs.  Certainly one of the major
trends affecting the health care system in
Europe at this time is harmonization, including
the registration of pharmaceuticals.  Even
though we’re working to harmonize the
registration of pharmaceuticals, the individual
member States are still responsible for their
own health policy, including payment policies
for medicines.  This can cause tension among
countries that adopt conflicting policies
regarding payment for a given drug.  We are
working to harmonize health policy across
member countries of the European Union.
Angaran: Mary Anne, a similar question to you.
What features do you think generally
characterize the U.S. health care system today,
and what are the emerging trends likely to
affect pharmacists and their patients over the
next 5 years?
Koda-Kimble: I think the phrase “health care
system” is an oxymoron as it describes the U.S.
The last decade produced tremendous change,
which actually resulted in a sense of turmoil
among both patients and health care providers.
In the minds of some people, this has reached
crisis proportions.  Driven by economics and
the high cost of health care, there has been a
corporatization of health care in the U.S.  This
has included consolidation, efforts to increase
efficiency, and increased demand to
demonstrate added value for the money spent.
But it is disconcerting that in this drive to
increase efficiency and, at least theoretically, to
simplify health care, we have created a system
that is even more complex and bureaucratic
from both a patient and provider perspective.
There are more layers between providers and
patients, and more barriers to the provision of
direct care.  Health care has become more
impersonal and continuity in health care
delivery has actually decreased.
Angaran: Kathy, following up on the remarks by
Bert and Mary Anne, we recognize that
pharmacy is only one part of the medication
use system.  There are other health professionals,
nurses and physicians and a lot of other people,
involved.  How well would you say the medica-
tion use system is performing today?  How are
the other health professions, government, and
consumers responding to the need to improve
the medication use system?
Lake: In general, the medication use system in
the U.S. is not performing very well.  Although
a number of publications point out the
problems with our medication use system, I’ll
comment on only two of them.  Tim Lesar and
colleagues have published a series of papers
that examine medication and prescribing errors
in the hospital setting.2–4 Over a 9-year period,
the number of such errors increased dramati-
cally.  Second, the work done by Bootman et al
in the long-term care setting suggests that
$1.33 is spent on managing the consequences
of medication-related morbidity and mortality
for every $1 spent on the medications
themselves.5 Something is definitely wrong
when we are spending more money on the
problems associated with the use of medication
than on the medication itself.
Unfortunately, I’m not sure that consumers
and the government in general are truly aware
of the magnitude of this problem.  (Editor’s
Note:  Dr. Lake’s comments preceded publication
of the report, “To Err is Human” by the Institute
of Medicine, which summarized evidence
documenting the extent of medical and
medication-related errors in the U.S.6)  As a
profession, we need to take a leadership role to
document the magnitude and costs of these
problems.  In many respects, our entire system
of medication use needs to be reengineered.
But it’s not our problem alone.  Medicine,
nursing, and all health professions concerned
with medication use must agree that a problem
exists and collaborate to conceive and
implement a viable solution.  Multidisciplinary
collaboration will be key—both to finding a
solution and as part of the solution itself.
Angaran: Joaquim, Kathy summarized some of
the issues that characterize the medication use
system in the U.S.  How do Europeans perceive
these issues, and do you also see the need to
improve the medication use system in Europe?
Bonal: Yes, we have similar problems in our
medication use system.  For example, we
recently found that 19% of patients admitted to
our hospital by way of the emergency room
were hospitalized because they had a
medication-related problem.  Further, 29% of
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patients taking some sort of medication prior to
presentation to the emergency room had
problems related to those medications.  These
data suggest that problems associated with
medication use in the community setting are of
a tremendous magnitude.  Cooperation and
collaboration between hospital and community
pharmacists, and between pharmacists and
primary care physicians, will be necessary to
solve this problem.  But to provide the pharma-
ceutical care required in the community, our
pharmacists must be allowed to exert a higher
level of authority in the decision-making
process for medication use.  This will require
support from governmental authorities to
enable pharmacists to expand their scope of
professional practice.
Angaran: Grethe, health care consumers’ and
patients’ roles in, and attitudes toward, the
health system are changing.  In America,
consumers are much less trusting.  They ask
more questions.  They look for information on
their own.  And they expect to be more respon-
sible for their own care.  Do you perceive a
similar change in Europe?
Eide: We have national heath care systems in
most European countries.  Consequently,
people have traditionally taken less
responsibility for their own heath care.  But
now, we are also experiencing a gap between
the demand for health care and access.  Hence,
a commercial private market for health care is
emerging in Europe.  There is also a growing
demand for alternative medical care, suggesting
that there is less trust in traditional medicine.
People are more aware.  They are more
questioning.  Unfortunately, their information
often comes from advertisements or articles in
lay magazines that may not be as complete or
unbiased as we would like.
We are also experiencing a growth in the
elderly population, although this growth rate
varies among countries.  Also as important, we
have a growing group of middle-aged people
with lifestyle diseases.  Many of these
consumers have realized the strength that lies
in numbers and have established advocacy
organizations according to their disease
(diabetes, asthma, organ transplantation, etc.).
These groups, who often have strong ties to the
pharmaceutical industry, are very effective in
representing their interests to health authorities
and politicians.
This consumer advocacy is accompanied by
a push from the government to encourage
people to take more personal responsibility for
their health, especially when it comes to
lifestyle modification.
Angaran: Kathy, Grethe eluded to the emerging
role of the consumer in health care.  What
effects are these changes in consumer attitudes
having on the medication use system in the
U.S.?
Lake: The changing consumer is affecting
medication use in at least two ways.  First, as a
general rule, consumers are much better
informed than they used to be.  Second, as
Mary Anne mentioned earlier, there is a
growing frustration among consumers with the
traditional health care system.
A growing number of patients can access a
lot of information by way of the Internet that
they used to be able to get only from a medical
library.  It is not unusual for a patient to
present to his or her physician or pharmacist
carrying some information downloaded from
the Internet.  As Grethe eluded to, this
information is uncontrolled and sometimes of
questionable accuracy and integrity.  The
modern health care consumer can be very
astute.  They may even “shop around.”  We
have had patients ask about our exact patient
and organ transplant survival rates.  They want
to know exactly what medication protocols are
available at our institution.  One negative
repercussion of this enhanced consumerism is
that we have actually experienced difficulty
maintaining blinding in clinical research
studies because patients have used chat rooms
to talk about the studies and can figure out
which individuals are on which treatments.
Of course, purchasing prescription medica-
tions from Internet pharmacies is already here.
My children’s generation will think nothing of
shopping over the Internet—for clothes, toys,
and prescription medications.  This will present
a challenge to our traditional view of how
clinical pharmacy is practiced and how
pharmaceutical care is delivered.
However, just as there are patients who easily
access the Internet for health information, there
is a large segment of the U.S. population that
does not have access.  Many of these people are
among the elderly population and truly need
help with their medication use.  Because
Medicare does not provide for outpatient
medications, some are even forced to make the
choice between paying for their medications or
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buying food—food usually wins!  Further,
patients are getting very frustrated with the
health care bureaucracy.  They have lost access
to their family physician and often must make
an appointment weeks or even months in
advance—even for relatively acute illnesses.
This frustration, in part, is turning many
people to alternative forms of medicine.  We
are now learning that some nutritional
supplements or herbal remedies may actually
be contributing to patients’ drug therapy
problems.  Unfortunately, many patients won’t
spontaneously admit that they have been
taking an herbal product, and health care
providers do not always specifically ask about
such use.
Angaran: Bert, you’ve done some really nice
work on scenario analysis in which you
described the impact of new technologies,
robotics, and information technology on
pharmacy.  Can you expand your perspective
beyond pharmacy and talk about how these
emerging technologies will affect the whole
medication use system?
Leufkens: Certainly, technology is an important
driving force for future change in health care
delivery.  But is technology the most critical
driving force?  My answer is no.  We were
surprised by the results of a scenario analysis
we did some years ago to anticipate the
treatment of diabetes.  We found that the
organization of care, individual values, the
interrelationship between health care
professionals, and the economics of care were
more important than technology per se.
Of course, information technology is out
there, our children play with it, and it will have
a big impact.  But beyond information
technology, genomics will have a major impact
on health care in the future.  This will include
the development of new drugs based on
genomics, the ability to individualize therapy
better to specific patients, and of course, gene
therapy itself.
Unfortunately, we are nowhere near
answering the ethical questions raised by
genomics.  For example, should we screen for
certain genetically determined diseases?  And if
so, what responsibility does the insurance
company have to the patient?  So yes, tech-
nology is a driving force.  But the environment
in which technology is applied is even more
important.
Angaran: Mary Anne, it is estimated that
pharmacists filled 2.7 billion prescriptions in
this country in 1998.  It’s been projected that
this number will increase to 4 billion by 2002
or 2003.  From your perspective as one who is
preparing students to enter practice, what is
the impact on the practicing pharmacist of the
interaction between these projections and the
technological changes that Bert and Kathy
mentioned?
Koda-Kimble: These trends have not been lost
on the chain drug store industry nor on stock
market analysts.  The consequence of this
today is that there is a shortage of dispensing
pharmacists in the U.S.  Interestingly, 3 years
ago we demolished our compounding and
dispensing lab.  It was an emotional event for
some people, but we believed that dispensing is
not the best role for pharmacists in the future.
I believe that even more strongly today.  I also
believe that in the next few years there will be a
major redesign in the way drugs get to patients.
Many of us who practice clinical pharmacy do
not dispense drugs.  Some have tried to
integrate those functions, but I foresee a greater
uncoupling and separation of the provision of
what some people would now call
pharmaceutical care and the dispensing or drug
delivery process.
It has been suggested that the pharmacist of
the future will be much like an air traffic
controller, sitting in some remote tower with a
computer in front of him or her, having access
to a lot of information, and directing “drug
traffic”—that is, drug interventions and the
like.  That vision seems to be more and more
the case.  We must get more efficient.  The one
pharmacist–one patient model from the past
may not be the norm in the future.
Angaran: Joaquim, you have held important
positions within both the Spanish government
and World Health Organization related to drug
policy and management.  Certainly, society
guides health care through its government-
developed regulations, through ethics, and by
setting priorities.  Can you describe the societal
and political dynamics in Europe that will
affect the future medication use system?
Bonal: There are very substantial differences
between the U.S. health system and the
European health systems.  In Europe, as has
been pointed out, most countries have a state-
financed health system that provides access for
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everybody.  In general, the population is
satisfied with this public system, in part
because they could not afford to pay for their
health care directly.  But all systems have
advantages and disadvantages.  One disad-
vantage of the European public system is that
the money to fund it comes from the general
taxes, which cannot be increased without
limits.  This causes an obvious problem when
demand is growing and the resources are
limited.  Naturally, this has led the govern-
ments to establish various cost-control
measures.  With regard to pharmaceuticals, this
has included establishing a higher copayment
by the patient, price controls imposed on
manufacturers, and reducing public financing
for some drugs with negative risk profiles.  In
general, these measures have had very limited
results.  Occasional conflicts occur between the
population-based health system like that found
in most countries in Europe and individual
patient care.  In other words, what may be best
for society as a whole may not be best for a
specific individual.
Angaran: Grethe, you’ve been involved in
developing new hospital and community-based
practices in Norway.  From your perspective,
where is Europe now in the development of the
pharmaceutical care concept in community
practice?
Eide: As you know, the largest part of
medication use occurs in the community health
care setting.  In general, Europeans are just
beginning to implement the pharmaceutical
care philosophy.  As expected, there are great
variations within countries and from one
country to another.  However, success has
come as a result of a greater focus on the
consumer’s needs and the requirement to
establish quality assurance systems in
community pharmacies.
But providing pharmaceutical care requires
knowledge and skills that few pharmacy
schools in Europe provide to their students.
Newly graduated pharmacists may know a lot
about drugs, but they know very little about
patients.  Hence, the role models these students
encounter when they enter practice, and on-
the-job training available to them, are very
important.  A drive is underway to change
pharmacy practice in many European
countries, and there are several national
demonstration projects that have begun.
Angaran: Mary Anne, many U.S. pharmacists
have adopted the pharmaceutical care
philosophy.  Ten years ago you made some
interesting observations about the diffusion of
this philosophy into community practice.
Where are we now in making this concept a
reality, and where do you think we will be 5
years from now?
Koda-Kimble: It’s important to realize that
pharmaceutical care is not the sole property of
pharmacy.  Pharmaceutical care is provided by
nurses, physicians, and many other
practitioners.  We want to take ownership of it
because it has “pharma” in front of it.  In my
view, clinically trained pharmacists are alive
and well.  Despite all of the changes,
challenges, and turmoil we have discussed thus
far, this very change and turmoil has created
many new opportunities.  Clinical pharmacists
in institutional practice have documented very
well the value of their services.  Now, these
practitioners are moving into community or
ambulatory care.  Certainly, managed care has
opened up many new opportunities for clinical
pharmacists.  We are applying the same
principles and concepts in the managed care
environment that we learned in the
institutional setting.  Some of my residents
have joined Internet-based pharmacies where
they are dispensing individualized information,
not drugs.  Clinical pharmacists are partnering
with physician groups.  The pharmaceutical
industry has recognized the value of the
clinical pharmacist and represents an
expanding career opportunity.  I feel very
optimistic about all of this.  I must admit,
though, that I’m not so optimistic about the
future of pharmacy practice if it is based
principally on the dispensing of drugs.
Angaran: During the first part of this session, we
have tried to describe two cultures that, even
though separated by an ocean, sound
remarkably similar.  We would now like to
focus on pharmacy, and the challenges and
opportunities that lie ahead.  Joaquim, the
practice philosophy of pharmaceutical care
embodies one central notion—a shared
responsibility by pharmacists for patient
outcomes.  Where is European pharmacy in
assuming this shared responsibility?
Bonal: Adoption of pharmaceutical care as a
philosophy of practice is growing.  For
example, in Spain a group of community
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pharmacists recently created the Pharmaceutical
Care Foundation.  Also in Spain, ambulatory
patients in some communities receive care from
hospital-based specialist physicians.  This has
provided a new opportunity for hospital
pharmacists to participate in primary care and
to cooperate with pharmacists working in the
community setting.  This allows direct
communication and cooperation among
different professionals to improve drug use in
the community.
The questions are, how can we, as pharmacists,
be allowed to take more responsibly for the
prescribing and use of drugs?  How can
community pharmacists be paid for their
professional services?  I think the answers to
these questions will come only when we have
enough documentation that the pharmacists’
services are improving the health of the
population and benefiting the overall health
system.
Angaran: Kathy, how can we improve our
current situation in the U.S. with regard to
pharmacists broadly assuming shared
responsibility for the pharmaceutical care of
their patients?
Lake: We really need a profession-wide
transformation.  So many pharmacists cling to
the old ways of practicing and doing business.
We heard comments earlier about our
dysfunctional medication use system.  The
evidence is already strong that pharmacists can
help solve these problems.  We have an
opportunity right now if we pull together.
Every pharmacist should consider it his or her
duty to tell patients and other health
professionals about the value of clinical
pharmacy services.  In addition, we all should
make a commitment to get involved politically
and to communicate the benefits of clinical
pharmacy services at every opportunity.
Angaran: Mary Anne, as a pharmacy educator,
what further changes are necessary in
pharmacy education to prepare our graduates
to assume this shared responsibility for
providing pharmaceutical care?
Koda-Kimble: Over the last few years, the
obvious big event that’s happened in the U.S. is
the adoption of the Doctor of Pharmacy as our
single entry-level degree.  That has, of course,
caused tremendous change across the country
as schools augment and revise curricula to
increase the clinical component.  And that is
good.  But here is where I worry.  I think we
need to go back to the basics.  Some of us can
remember that pharmacist of years past who
took the initiative, who took risks, who was
entrepreneurial, who cared, who made
decisions out there in the field.  I believe our
profession has lost many of those values and
qualities, but we need them back in the
pharmacists that we’re training for the future.
Second, science is the basis of a profession.  I
fear that we are discarding some of the basic
sciences in our curriculum in favor of the
clinical sciences.  Speaking for myself as a
clinician, I am sometimes at a loss,
conceptually, when I read about many of
today’s new drugs because the pace of
discovery in the basic sciences has been so
astounding.  For the pharmacists that we are
training now, as well as the professionals
already in practice, basic science must be part
of our entry-level and continuing professional
education.  Further, we also have to be
knowledgeable about health care systems,
politics, and economics.  Because of the
importance of documenting the value of
pharmacy services to patients and the health
system, now and in the future, every student
should also have some rudimentary skills in
pharmacy practice research.
Angaran: Grethe, you’ve been interested in
clinical pharmacy education in Europe for
quite some time.  Could you comment and
expand on Mary Anne’s remarks from a
European perspective?
Eide: In Europe, clinical pharmacy has generally
not yet been accepted as part of pharmacy
education.  Most undergraduate programs are
based on the natural sciences.  Although there
have been some major changes through the
years, with greater emphasis on pharmaco-
therapeutics and problem-based learning,
clinical pharmacy is still more a part of
graduate programs—like master’s degree
programs or hospital pharmacy specialization
programs.  In addition, the number of students
able to enter such clinical programs is limited
because there are few programs available.
Angaran: Bert, we have described a number of
changes in society, health care, and
therapeutics.  From your perspective, what
would you suggest the research agenda should
be to support our evolving profession?
Leufkens: First of all, I agree with Mary Anne
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that science is an integral part of our
profession.  In the Netherlands, we are
fortunate that all pharmacy students have a 6-
month research experience as part of their
undergraduate training.  This experience is
important not only in developing their
scientific skills but also in shaping their
attitudes toward science as they enter practice.
It also provides a link between academia and
practice.
But to directly answer your question, there
are two areas of research that I believe need
much greater emphasis:  pharmacy practice
research and pharmacoepidemiology.  As in the
U.S., the need for pharmacists to do practice
research to document the value of their
expanding services is very real.  Pharmaco-
epidemiology is important because of the issue
of drug-related problems.  We know so little
about a drug’s effects after it is released on the
market, yet the problems are very real.
Angaran: Grethe, the same basic question to
you:  from your perspective as a community
practitioner in Europe, what should the
pharmacy research agenda be to support your
needs?
Eide: My ideas parallel those of Bert.  I see three
very important areas.  The first is postmarketing
studies regarding drug safety and efficacy.
Despite all the money put into clinical trials,
they test a drug in very limited groups and
often don’t really predict what happens when
the drugs are used more widely.  Second is
outcome and pharmacoeconomic studies.  And
third is more research on pharmacy practice to
assess how pharmacy intervention can be cost-
effective to society.
Angaran: Joaquim, how health care and
pharmacy services are financed in many
European countries is much different than in
the U.S.  From your perspective, what political
and regulatory changes will enable clinical
pharmacy diffusion within Europe?
Bonal: Pharmacists need governmental authority
to assume more responsibility in the drug
therapy decision-making process.  But because
laws always follow social change, efforts should
be made to obtain more evidence that clinical
pharmacy services enhance patient outcomes
and improve the health care system.
Unfortunately, we have very little documen-
tation to that effect in Europe.
Also, there are large differences between the
schools of pharmacy in the U.S. and those in
Europe.  Although some schools of pharmacy
in Europe are supportive of clinical practice,
others actually oppose the concept.  This
creates a gap, which must be resolved, between
the schools of pharmacy and the practitioners.
More practitioners must be involved in the
university.
Angaran: Mary Anne, these dynamic changes in
society and health care are going to result in
some very interesting ethical issues that our
profession and practitioners have not had to
face before.  Can you comment?
Koda-Kimble: I think it is going to be a huge
challenge to maintain a focus on our core
values as a profession, not because of the shift
in emphasis but because of who’s controlling
health care.  Who delivers care, who gets care,
and what kind of care will be delivered?  It is
being driven more by businessmen and less by
the independent practitioner.  The other
challenge for us as pharmacists will be to take a
stand on some of the larger issues.  For
example, should drugs be covered by health
insurance and Medicare?  Our positions will
likely find us on the opposite side of the issue
from the pharmaceutical industry.  At the same
time, we are trying to collaborate, cooperate,
and develop partnerships with industry.  This
will be a real challenge.
Angaran: To conclude, I would like to ask each
of our panelists for their recommendations.
What can individual pharmacists do, what can
pharmacy education do, and what can
pharmacy organizations do to help position our
profession to best meet the pharmaceutical care
needs of society?
Leufkens: First, pharmacists must be innovative
and assume leadership roles in their
environments.  The gap between community
and hospital practice must be eliminated.
Many diseases once treated predominantly in
the hospital are now managed in the
community.  Continuity of care is crucial.
Second, as educators we must do a better job
to provide our students with enhanced
communication and cognitive skills, as well as
an appreciation for science.  Finally, I am a
strong believer in individual leadership.
Pharmacy associations must do a better job
identifying the key leaders among their
membership, put them in place, and let them
do their job.  Too many professional organi-
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zations become very bureaucratic and do not
allow the members to guide the association.
Koda-Kimble: Pharmacists must be at the table
to influence change.  It is easy to be
overwhelmed by all the changes taking place.
But we have to remember that it is one
pharmacist at a time, one patient at a time, one
action at a time.  To the extent that every single
pharmacist can take responsibility for what he
or she can control, we will begin to move
forward.
With regard to pharmacy education, our
responsibility is to inspire.  We are creating a
future.  We need to create a sense of idealism
and a vision.  Students must enter practice
dissatisfied with the status quo and sustain that
attitude throughout their careers.  As it relates
to professional organizations, I would ask them
to emulate the marketplace.  They need to
consolidate, or at the very least to collaborate.
They need to find a single message that will
communicate the value of pharmacists to the
public.  “Pharmaceutical care” is not that
message.  It is too complicated.  We need to
break it down into something simple, and we
need to all be repeating the same message every
time.  The pharmaceutical industry has done
this:  they create new drugs to cure disease.
What do pharmacists do?
Eide: It is important that consumers be
convinced that they can trust their pharmacist,
and individual pharmacists must be cautious
not to violate that trust.  As far as pharmacy
education is concerned, schools in Europe
should analyze society’s needs for improved
drug therapy outcomes and produce
pharmacists capable of addressing those needs.
Professional organizations must convince
health authorities of the beneficial impact
pharmacists can have on drug use and on
health care budgets.
Bonal: Many pharmacists must change their
attitudes about professional practice and
improve their clinical knowledge and skills.  In
Europe, the schools of pharmacy have to
change their curricula completely.  The current
curriculum is no longer acceptable.  They must
start by defining the objectives of pharmacy
education.  Many schools educate pharmacists
to work in the pharmaceutical industry and
governmental agencies dealing with food
control and other things that have nothing to
do with the use of drugs.  And finally,
pharmacy organizations have to exert more
political pressure.  They must work to expand
the authority of pharmacists and must pressure
the schools of pharmacy to change their
programs.  They also have to promote and
finance research projects to document
pharmacists’ contributions to better health.
Lake: All pharmacists must make a commitment
to improve the therapy of their patients.
Beyond that, I would like to see each
pharmacist commit to educating someone else
about the value of our services—not just an
administrator in his or her institution, but
patients, legislators, insurance companies, etc.
This will take many people outside their
comfort zones, but it can have a major impact.
Concerning pharmacy education, schools
should develop their curricula with the desired
outcomes in mind.  What knowledge and skills
does a pharmacist need to optimize drug
therapy outcomes?  Every aspect of the
curriculum must work toward that end.  And
finally, this is a crucial time for our professional
associations to work together.  There may be
certain organizations whose constituents prefer
the status quo.  But there is some urgency in
redefining pharmacy’s societal role.  We have a
challenge, yes.  But we also have a tremendous
opportunity, and I am confident that we will
succeed.
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